Finanzen von Strata Skin Sciences Inc (SSKN)SSKNStrata Skin Sciences Inc

Strata Skin Sciences Inc (SSKN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Dermatology Recurring Procedures, accounting for 66.8% of total sales, equivalent to $5.12M. Another important revenue stream is Dermatology Procedures Equipment. Understanding this composition is critical for investors evaluating how SSKN navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Strata Skin Sciences Inc maintains a gross margin of 60.38%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -26.80%, while the net margin is -23.41%. These profitability ratios, combined with a Return on Equity (ROE) of -204.07%, provide a clear picture of how effectively SSKN converts its operational activities into shareholder value.

In the context of the broader market, SSKN competes directly with industry leaders such as TIVC and BBLG. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, SSKN's gross margin of 60.38% stands against TIVC's N/A and BBLG's N/A. Such benchmarking helps identify whether Strata Skin Sciences Inc is trading at a premium or discount relative to its financial performance.

In Q3 2025, revenue dropped by 21.23% YoY to $6,929,000, net income fell by 21.79% YoY to -$1,622,000, and EPS declined by 29.41% YoY to -$0.36. Gross margin increased slightly to 60.38%, up 0.48% YoY, but this is insufficient to offset the overall poor financial performance.